Business Wire

MI-EATON

Share
Eaton to showcase innovative electrified commercial vehicle technologies at IAA Transportation show

Power management company Eaton will display technologies to support the zero emissions journey in the commercial vehicle market Sept. 20-25 at the IAA Transportation show in Hannover, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220908005014/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s eMobility business provides electrified vehicle solutions for its global commercial vehicle customers. (Photo: Business Wire)

“We are helping our customers around the globe with technologies that solve some of the toughest challenges throughout the electrified vehicle (EV) ecosystem,” said Scott Adams, president, Eaton’s eMobility business. “Eaton provides a vast portfolio of EV technologies for full battery electric, fuel cell and hybrid commercial vehicles, as well as EV charging infrastructure solutions.”

Flex Power Distribution Unit delivers safe power for commercial electrified vehicles

Eaton’s eMobility business offers a new Flex Power Distribution Unit (PDU) for high-voltage electrified commercial vehicles that is uniquely designed to handle multiple load requirements.

The Flex PDU integrates Eaton’s Breaktor® circuit protection technology, which improves vehicle safety and protects components from any level of overcurrent condition more effectively than traditional circuit protection methods. The Breaktor circuit protection solution is resettable like a circuit breaker, enabling reactivation of the device following a functionality check and reducing cost for both the OEM and consumer.

The Flex PDU also leverages sealed and corrosion-resistant terminals and connectors from Royal Power Solutions, a global leader in power distribution and transmission solutions that Eaton acquired earlier this year. Eaton’s Bussmann® series fuses are also integrated to meet the requirements for use in the latest high-powered electrified vehicles with ratings up to 1,000 volts of direct current (VDC) and 600 amps.

Eaton’s Flex PDU protects vital components and occupants and is also an intelligent unit that provides the OEM diagnostic information, including where the most power is being consumed, to maximize performance and efficiency. Its integrated and optimized design reduces the number of components, lessening complexity.

Electrified vehicle transmissions, gearing improves performance, range

Eaton’s new 4-speed transmissions provide superior performance on grades and acceleration for electrified commercial vehicles while offering more flexible gear ratios compared to competitive technologies. The compact 4-speed transmissions for medium- and heavy-duty electrified commercial vehicles also improve system efficiency, enabling longer vehicle range and battery life.

“We supply transmissions for multiple global commercial vehicle manufacturers, and many more are interested,” Adams said. “With decades of experience, we continue to build on our heritage as a top supplier of commercial vehicle transmissions.”

DC-DC converters available in a range of power configurations

Eaton recently introduced a 48-volt DC-DC converter to power accessories such as antilock brakes and lighting for commercial vehicles with 48-volt electrical systems. Unlike competitive offerings, Eaton’s DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency.

Eaton’s DC-DC converter portfolio covers a spectrum of power requirements, ranging from low- to high-voltage systems, depending on customer specifications. The converters can be tuned for particular duty cycles via their advanced digital control architecture, enabling flexible control modes through firmware adaptation.

Green Motion acquisition bolsters Eaton’s vehicle charging capabilities

In March 2021, Eaton acquired Switzerland-based Green Motion SA, a leading designer and manufacturer of electric vehicle charging hardware and related software. Eaton’s efficient electric vehicle charging infrastructure expertise includes the production and operation of charging stations, designing management software for charging networks, and serving as an electric mobility service provider.

‘Buildings as a Grid’ strategy expands charging possibilities

Many workplaces host vehicle fleets, such as cars for the salesforce and vans for deliveries. Fleet managers switching to EVs, either now or in the future, will want to electrify their fleet while ensuring business continuity. Eaton’s “Buildings as a Grid” approach helps fleet managers devise an EV charging strategy that is fast to implement, cybersecure and scalable so that they can add more EV charging capacity when needed.

The strategy may include EV charging infrastructure at their site or depot, on-site renewables like solar panels on buildings, and options for fleet drivers to charge at home and when they are traveling. Eaton’s digital and physical infrastructure transforms a workplace or depot into an energy hub, and because it is a gateway to electrifying the entire functionality of the site, it is also an investment in the energy transition.

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. Eaton is guided by its commitment to do business right, operate sustainably, and to help its customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, Eaton is accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for its stakeholders and all of society.

Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005014/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye